TCM
ARQT icon

Triumph Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Triumph Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Sell
900
-14,235
-94% -$332K ﹤0.01% 886
2026
Q1 		$357K Buy
15,135
+14,235
+1,582% +$363K 0.07% 239
2025
Q4 		$26.1K Buy
+900
New +$23K 0.01% 791
2025
Q3 		– Sell
-29,244
Closed -$410K – 322
2025
Q2 		$410K Buy
+29,244
New +$410K 0.12% 188

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Triumph Capital Management's ARQT Position: Q2 2026 in Review

Triumph Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 94% in Q2 2026, selling an estimated $332K and leaving 900 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Triumph Capital Management first reported a position in ARQT in Q2 2025 and has held it in 4 quarters since. The position peaked at $410K in Q2 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Triumph Capital Management held 900 shares of Arcutis Biotherapeutics worth $23.6K as of Q2 2026.
  • Triumph Capital Management sold 14,235 Arcutis Biotherapeutics shares in Q2 2026, an estimated $332K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #886 holding.
  • Triumph Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • Triumph Capital Management's Arcutis Biotherapeutics position peaked at $410K in Q2 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.